Kyverna Therapeutics is trading at $7.50, up 6.08%, after announcing positive one-year KYSA-8 data in stiff person syndrome and longer-term KYSA-6 results in generalized myasthenia gravis.

  • The company reported sustained clinical benefits and favorable safety findings; the rolling BLA submission for miv-cel remains on track for Q4 2026.
  • Kyverna scheduled an 8:00 a.m. ET conference call to review the data.